price, page-14

Agree about the safe hands.

I was trying to look at the downside for SBN and the only things I could come up with were:

a. may be no FDA approval? But knowing the process, the worst case scenario is the FDA could ask for more data, which may mean a delay, but I think approval is a given.

b. Chinese govt doesn't give approval for new manufacturing company? If they don't, which I doubt, then there are lots of other countries in the world to do business with and besides that announcement hasn't been built in by the market. The market aslo hasn't realized what the exclusive sales to China could mean.

c. Nobody interested in buying the product? Already been discussed that demand out strips supply.

d. No big distribution or deals on the horizon? Simply no competitors that offer the sensitivity or the patented collection device Oraline has.

e. The company could run out of money? Just finished a very modest placement and if the company wasn't confident of deals in the pipeline they would have gone for more. That's seems obvious.

I suppose that's why I hold.

cheers